Abstract:Léa El Haddad, 1 Mainur Khan, 1 Rania Soufny, 1 David Mummy, 2 Bastiaan Driehuys, 2 Wissam Mansour, 3 Priya S Kishnani, 4 Mai K ElMallah 1 1 Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA; 2 Department of Radiology, Duke University Medical Center, Durham, NC, USA; 3 Division of Pulmonary and Sleep Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA; 4 Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA Correspondence: Mai K ElMallah, Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Duke University Medical Center, Box 2644, Durham, NC, 27710, USA, Tel +1-919-684-3577, Email Pompe disease (PD) is a neuromuscular disorder caused by a deficiency of acid alpha-glucosidase (GAA) – a lysosomal enzyme responsible for hydrolyzing glycogen. GAA deficiency leads to accumulation of glycogen in lysosomes, causing cellular disruption. The severity of PD is directly related to the extent of GAA deficiency – if no or minimal GAA is produced, symptoms are severe and manifest in infancy, known as infantile onset PD (IOPD). If left untreated, infants with IOPD experience muscle hypotonia and cardio-respiratory failure leading to significant morbidity and mortality in the first year of life. In contrast, late-onset PD (LOPD) patients have more GAA activity and present later in life, but also have significant respiratory function decline. Despite FDA-approved enzyme replacement therapy, respiratory insufficiency remains a major cause of morbidity and mortality, emphasizing the importance of early detection and management of respiratory complications. These complications include impaired cough and airway clearance, respiratory muscle weakness, sleep-related breathing issues, and pulmonary infections. This review aims to provide an overview of the respiratory pathology, monitoring, and management of PD patients. In addition, we discuss the impact of novel approaches and therapies on respiratory function in PD. Keywords: Pompe disease, respiratory complications, respiratory monitoring, respiratory therapy Pompe disease (PD), or glycogen storage disease type II, is an autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA) - an enzyme responsible for hydrolyzing lysosomal glycogen. 1 PD is a neuromuscular disorder characterized by systemic lysosomal glycogen accumulation causing diffuse cellular disruption in muscles and motor neurons. PD encompasses a broad spectrum of disease severity ranging from severe infantile-onset to late-onset Pompe disease (IOPD and LOPD, respectively). The classification of PD is determined by the age at diagnosis, amount of the residual GAA enzyme activity, and cardiac involvement. 2,3 In untreated infants with IOPD, symptoms can manifest at birth or in the first few weeks of life. These symptoms include muscle hypotonia, cardiomegaly, and respiratory decline, ultimately leading to cardiorespiratory failure and death within the first 2 years of life. 2 On the other hand, LOPD can present at various ages, ranging from early childhood to adulthood. A key distinguishing feature of LOPD is the absence of cardiomyopathy in the first year of life. 2 To date, the only FDA-approved treatment for PD is enzyme replacement therapy (ERT) with human recombinant GAA (rhGAA). rhGAA breaks down the excess glycogen in the lysosomes and improves muscle function. A meta-analysis performed on the efficacy of ERT in patients with LOPD revealed a significantly improved walking distance on the six-minute walk test. 4 However, the respiratory function and muscle strength in these patients remained unchanged. 4 In contrast, other studies have shown stable respiratory function and improved motor function with ERT in LOPD patients. 5 Similarly, increased ventilator-free survival is seen in IOPD patients. 6 Despite improved clinical outcomes in patients treated with ERT, the clinical response to ERT varies considerably between patients due to many factors including age, stage of treatment, dose of ERT, the Cross-Reactive Immunological Material (CRIM) status, and muscle fiber type. 7,8 CRIM-positive (CRIM+) patients produce some residual but nonfunctional GAA enzyme and better tolerate ERT. They typically have low neutralizing antibody titers against rhGAA, making the treatment effective. On the other hand, CRIM negative (CRIM-) patients are unable to produce any GAA protein and generally do not tolerate ERT because of a significant immune response against rhGAA resulting in respiratory decline, ventilator dependence, and -Abstract Truncated-

Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease

Interplay between mitochondrial dysfunction and lysosomal storage: challenges in genetic metabolic muscle diseases with a focus on infantile onset Pompe disease

Current Knowledge and Results of an Italian Study

Pompe Disease in China: Clinical and Molecular Characteristics

Decoding the muscle transcriptome of patients with late onset Pompe disease reveals markers of disease progression

Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease

Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease

Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice

Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model

Molecular Approaches for the Treatment of Pompe Disease

Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy

Pompe Disease: New Developments in an Old Lysosomal Storage Disorder

Mitochondrial Dysfunction is Associated with Hypertrophic Cardiomyopathy in Pompe Disease-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes

Defect in degradation of glycogenin‐exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease

Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease: a comprehensive cardiovascular magnetic resonance approach

Prominent Respiratory Involvement Featured in High-Risk Screening for Late-Onset Pompe Disease in China

Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives

Mutational spectrum and genotype-phenotype correlation in Mexican patients with infantile-onset and late-onset Pompe disease